Pancreatic cancer
Conditions
Interventions
Experimental group:Organoid establishment
According to the results of drug sensitivity to organoids, a more sensitive drug regimen was adopted
Sponsors
Department of hepatobiliary Surgery, 13th floor, main ward building, Xinqiao Zhengjie, Xinqiao Hospital, Shapingba District, Chongqing
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: ? Patients aged 18-75 years old, both male and female; ? The ECOG score is 0-2; ? Patients with clinically determined borderline resectable pancreatic cancer who are scheduled for neoadjuvant therapy; ? Fresh tissue specimens sufficient for organoid establishment can be obtained by puncture; ? Patients with pancreatic ductal adenocarcinoma confirmed by histopathology and/or cytology; ? The patients voluntarily joined the study and signed the informed consent, with good compliance and follow-up
Exclusion criteria
Exclusion criteria: ? Patients who have previously received systemic therapy for pancreatic cancer ? Patients with clinically determined resectable pancreatic cancer, locally advanced pancreatic cancer, and metastatic pancreatic cancer ? Patients who have had other malignant tumors within 5 years, except skin cancer that has been cured; Patients who have had clinically important (i.e. active) heart disease (e.g. congestive heart failure, symptomatic coronary artery disease, arrhythmia, etc.) or myocardial infarction within the past 12 months; ? Patients who have a history of psychotropic drug abuse and cannot quit or have mental disorders;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease-free survival; | — |
Countries
China
Contacts
Public ContactHuang Xiaobin
the Second Affiliated Hospital of the PLA Army Military Medical University
Outcome results
None listed